SCHEMBL3199765

SCHEMBL3199765

COc1ccc(NC(=O)c2ccc(Cl)nc2)c(O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 1/20 0.56
KCNQ3 O43525 2/20 0.55
KCNQ2 O43526 2/20 0.55
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
F10 P00742 2/20 0.53
MAPT P10636 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
RAB9A P51151 3/20 0.53
NR2F2 P24468 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
TP53 P04637 2/20 0.51
MDM4 O15151 1/20 0.51
MDM2 Q00987 1/20 0.51
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
POLB P06746 1/20 0.49
TSHR P16473 1/20 0.49
TAS1R3 Q7RTX0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303029 0.88 KMT2A (0.59) P4HTMKCNQ3KCNQ2MEN1KMT2A
SCHEMBL4061498 0.88 P4HTM (0.72) P4HTMKCNQ3KCNQ2MEN1KMT2A
SCHEMBL1233658 0.86 P4HTM (0.55) P4HTMKCNQ3KCNQ2MEN1KMT2A
SCHEMBL19405896 0.86 MDM4 (0.52) KCNQ3KCNQ2MEN1KMT2AMAPT
SCHEMBL21462534 0.85 MDM4 (0.57) KCNQ3KCNQ2MEN1KMT2AMAPT
SCHEMBL3199904 0.84 DEGS1 (0.56) P4HTMMEN1KMT2AF10MAPT
SCHEMBL19405814 0.83 MDM4 (0.54) KCNQ3KCNQ2MEN1KMT2AMAPT
SCHEMBL6705958 0.82 MAPT (0.68) MEN1KMT2AMAPTSMN1; SMN2RAB9A
SCHEMBL944688 0.82 NAPRT (0.57) P4HTMKCNQ3KCNQ2MEN1KMT2A
SCHEMBL2302302 0.80 RAB9A (0.72) P4HTMKCNQ3KCNQ2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7670591-B2 Heteroaryl substituted benzoxazoles ASTRAZENECA AB (SE) 2010-03-02 US disclosed
US-7670591-B2 Heteroaryl substituted benzoxazoles ASTRAZENECA AB (SE) 2010-03-02 US disclosed
US-7670591-B2 Heteroaryl substituted benzoxazoles ASTRAZENECA AB (SE) 2010-03-02 US disclosed
EP-2035418-A1 NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES Astra Zeneca AB (SE) 2009-03-18 EP disclosed
US-20080027051-A1 Novel Heteroaryl Substituted Benzoxazoles ASTRAZENECA AB (SE) 2008-01-31 US disclosed
US-20080027051-A1 Novel Heteroaryl Substituted Benzoxazoles ASTRAZENECA AB (SE) 2008-01-31 US disclosed
US-20080027051-A1 Novel Heteroaryl Substituted Benzoxazoles ASTRAZENECA AB (SE) 2008-01-31 US disclosed
WO-2007149030-A1 NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES ASTRAZENECA AB (SE) 2007-12-27 WO disclosed
WO-2007149030-A1 NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES ASTRAZENECA AB (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027051-A1 Novel Heteroaryl Substituted Benzoxazoles PSEN1, PSEN2, APP P4HTM 1915/4885KCNQ3 1021/4885KCNQ2 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.